Illumina is a leading company focused on genomic analysis, providing advanced tools and services for the study of genetic material in life sciences and clinical laboratories. Established in 1998 in San Diego, California, Illumina generates over 90% of its revenue from sequencing instruments, consumables, and related services. Its high-throughput technology facilitates whole genome sequencing for humans and large organisms, while its lower throughput tools cater to applications like viral and cancer tumor screening. Additionally, Illumina offers microarrays for cost-effective genetic screening, primarily in consumer and agricultural sectors. The company emphasizes collaboration and rapid delivery of innovative solutions, which are essential for advancing personalized medicine. Through initiatives like Illumina Accelerator, established in 2014, the company supports startups in the genomic industry by providing mentorship, financial assistance, and access to essential resources, fostering a dynamic ecosystem for innovation in genomics.
Dama Health specializes in pharmacogenetic technology aimed at providing personalized contraception recommendations for women and clinicians. The company employs genetic testing and an automated matching system that considers individual preferences, medical history, and specific requirements. By analyzing unique predispositions and the efficacy and side effect profiles of various contraceptive options, Dama Health enables women and healthcare providers to make informed and safe birth control decisions tailored to each individual's needs.
B4X, INC., a therapeutics and diagnostics company from Atlanta, Georgia, is utilizing multi-omic big data anchored in genomics to deliver life-saving therapeutics and precision diagnostics to individuals suffering from debilitating diseases of the brain.
NonExomics integrates genomics, transcriptomic, and proteomics data by utilizing proprietary machine learning approaches to predict structures of nonexomic proteins and identifies disease-specific nonexomic targets, allowing clients to find cures for rare diseases.
ImYoo Inc., a direct-to-consumer single-cell transcriptomics company from the California Institute of Technology, aims to deliver personalized, biology-driven health insights by connecting people with similar immune profiles to share their health journeys.
Genegoggle is a precision medicine biotech company with the goal of discovering novel therapeutics and intelligent systems to improve human health by leveraging multi-dimensional genomic and epigenetic elements.
Bixbio
Seed Round in 2021
Bixbio is a biotechnology company working to unlock the potential of diverse genetic data in Africa to transform the field of precision medicine.
Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies.
Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in genomic data compression software. Its primary product, Lena, enhances the speed and efficiency of next-generation sequencing (NGS) analyses while reducing storage costs and minimizing internal network traffic. The software is designed to maintain data integrity during compression and decompression processes, making it a valuable addition to existing informatics solutions in the field. As of July 2020, Enancio operates as a subsidiary of Illumina, further strengthening its position in the genomics industry.
Bluebee Holding B.V., based in Rijswijk, the Netherlands, develops a cloud-based genomics analysis platform that accelerates the processing of sequencing data. Founded in 2011, the company provides solutions for research centers, sequencing service providers, clinical labs, and kit providers, enabling them to manage, process, and share large volumes of genomic data efficiently and affordably. The platform is designed to address the challenges posed by the rapid advancements in next-generation DNA sequencing technology, offering high-performance computing and clinical-grade security. By facilitating faster data processing and deep analytics, Bluebee aims to enhance the implementation of whole genome diagnostics in clinical settings, ultimately supporting the development of personalized treatments and innovative healthcare solutions. As of June 2020, Bluebee operates as a subsidiary of Illumina, Inc.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Edico Genome Inc. develops bioinformatics processor chip that helps in DNA analysis. It offers DRAGEN bio-IT processor, a sequencing bioinformatics application-specific integrated circuit that is integrated on a PCIe form-factor card and is provided with accompanying software as a Platform-as-a-Service that is integrated directly into sequencing instruments and next-generation sequencing bioinformatics servers. The company was founded in 2013 and is based in La Jolla, California. As of May 14, 2018, Edico Genome Inc. operates as a subsidiary of Illumina, Inc.
Helixis
Venture Round in 2018
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Trace Genomics, Inc. specializes in developing artificial intelligence-based diagnostic tools for farmers, focusing on soil health and crop quality. The company offers a soil microbiome test that utilizes DNA sequencing and artificial intelligence to analyze microbial species in agricultural soils. By interpreting key indicators of soil health and disease risk, Trace Genomics enables early predictions of soil diseases, benefiting agronomists and their corporate partners. Founded in 2015 and headquartered in Burlingame, California, with an additional office in Ames, Iowa, Trace Genomics aims to enhance agricultural practices and maximize the value of every acre for the farming community.
Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.
Vitagene, Inc. is a health technology company that uses genomic science and advanced technology to create a DNA-based personalization platform for healthcare. It offers customized supplements directly to patients based on their individual needs for nutrition, sleep, exercise, and supplementation. The company's algorithm analyzes extensive patient data, including genetics, blood work, and lifestyle, to generate personalized supplement regimens. Vitagene also manufactures DNA health test kits and provides health and ancestry reports that outline dietary, supplement, and exercise recommendations. Additionally, the company produces at-home COVID-19 saliva test kits. Founded in 2014 and based in San Francisco, California, Vitagene aims to empower individuals with tailored health solutions through big data and machine learning.
MetaMixis Inc. is a biotechnology company based in Vancouver, Canada, founded in 2012. The company focuses on developing enzymes and metabolic pathways for microorganisms that produce chemicals. MetaMixis creates biosensors that leverage natural environmental processes to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a portfolio of enzymes and pathways capable of performing specific transformations. The founding team combines expertise in synthetic biology, environmental genomics, and bioinformatics, with the goal of advancing the bioeconomy through innovative enzyme and pathway discovery. The company has also established a knowledgeable board to guide its development and growth.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
GenoLogics, Inc. is a company specializing in laboratory information management systems (LIMS) designed to enhance the diagnosis and treatment of diseases. Their flagship product, BaseSpace Clarity LIMS, is utilized by research and clinical laboratories to effectively track samples from receipt to results, thereby improving accuracy, reducing costs, and ensuring high quality standards. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics aims to support translational medicine and systems biology initiatives through its collaborative data management software platform. As a subsidiary of Illumina, Inc., the company focuses on advancing life sciences research by facilitating early detection, prevention, and treatment of various diseases.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.
Human Longevity (HLI) is a health intelligence company focused on advancing proactive healthcare through genomic insights. Founded in 2013 and based in San Diego, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with machine learning, to enhance medical practices and foster discoveries in health. The company’s primary offerings include the HLI Health Nucleus, a clinical research center that integrates whole-genome sequencing, advanced imaging, and personalized health data to provide a detailed view of individual health. HLI also addresses significant health issues, such as cancer, diabetes, obesity, heart and liver diseases, and dementia, by leveraging DNA sequencing and expert analysis. Through its innovative approach, HLI aims to improve health outcomes and transition healthcare from reactive to proactive strategies.
Moleculo is a biotech company that focuses on developing technologies for generating long reads for genome analysis tools. The company has developed a novel DNA sequencing method that provides long and accurate reads, thereby improving the efficiency and accuracy of many existing DNA sequencing applications, enabling clients to get a range of new applications.
BlueGnome Limited specializes in developing genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Based in Fulbourn, United Kingdom, the company gained recognition for its innovative approaches to genetic testing. In 2012, BlueGnome was acquired by Illumina, a leading company in the field of genomics, further enhancing its capabilities and reach in the market for genetic diagnostics.
GenoLogics, Inc. is a company specializing in laboratory information management systems (LIMS) designed to enhance the diagnosis and treatment of diseases. Their flagship product, BaseSpace Clarity LIMS, is utilized by research and clinical laboratories to effectively track samples from receipt to results, thereby improving accuracy, reducing costs, and ensuring high quality standards. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics aims to support translational medicine and systems biology initiatives through its collaborative data management software platform. As a subsidiary of Illumina, Inc., the company focuses on advancing life sciences research by facilitating early detection, prevention, and treatment of various diseases.
Epicentre Biotechnologies
Acquisition in 2011
Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.
Helixis
Acquisition in 2010
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Solexa
Acquisition in 2006
Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.